GEN Exclusives

More »

GEN News Highlights

More »
Nov 30, 2006

Nycomed Will Pay Durect up to $202M in Posidur Development Agreement

  • Durect and Nycomed will jointly develop Durect’s Posidur™ post-operative pain relief depot. Posidur is currently in Phase II trials. Under the terms of the agreement, Nycomed will pay Durect an upfront license fee of $14 million, with additional milestone payments of up to $188 million upon achievement of defined development, regulatory, and sales milestones.

    The two parties will jointly direct and equally fund a development program for Posidur intended to secure regulatory approval in both the U.S. and the E.U.

    Nycomed will have exclusive commercialization rights in Europe and other select countries, and Durect will retain full ownership of Posidur in the U.S., Canada, Asia, and other countries. Durect will manufacture and supply the product to Nycomed for sale. Nycomed will pay Durect blended royalties on sales in the defined territory of 15–40% depending on annual sales.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?